威健
威健生技 Stock: price and insider trades · Taiwan
TW·Mcap NT$398.5M
威健生技: what insiders have been doing
Insider filings for 威健生技 are scarce in the TWSE / TPEx (MOPS) feed, the latest one published on 15 January 2021. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by TWSE / TPEx (MOPS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 21,469 of 26,911 companies
30.8
score / 100
Value29
Quality32
FCF yld-1.7%
Earn yld0.3%
EV/EBITDA19.2x
ROE-0.5%
Gross mgn42%
Net mgn0.4%
Debt/EBITDA6.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$17
Analyst consensus
Income statement
RevenueNT$375.9M
Gross profitNT$156.2M42% margin
EBITDANT$32.5M9% margin
Net incomeNT$1.3M-0.4% margin
Valuation
P/Book1.5x
Beta0.21
Balance sheet & cash
Market capNT$398.5M
Total debtNT$226M
Free Cash Flow-NT$6.8M
Debt / Equity101%
Profitability & ownership
ROE-0.5%
ROA-0.3%
% insiders72.1%
% institutions0.0%
Last declaration on 15 January 2021
Declarations1 total
- 123,000 sharesShareTPExTWMOPS:6661:110/01/15:漢碁股份有限公司:0v1vaee
1 of 1 declaration
About 威健生技
威健生技 is a company listed on the XTAI market, specializing in biotechnology. It focuses on developing innovative solutions to enhance human health.